Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Profile — Insider Trades & Financials

Net Income-$20.6M

EPS$-4.73

Market Cap$174.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Yuval Cohen

CEO & Executive Director

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Founded: 2009
Employees: 36
Headquarters: Norwood, Massachusetts, United States
Website

⚡

Core Efficiency

ROE?

-13.94%

ROA?

-12.22%

D/E Ratio?

0.14

📊

Profitability Ratios

Current Ratio?

8.07

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 14, 2026 (in 127 days)

Annual Report (10-K) — Based on filing pattern

Aug 14, 2026

Predicted10-K

Mar 9, 2026

10-KQ4 20253d after period end

Mar 9, 2026

10-KFY 202568d after period end

Nov 12, 2025

10-QQ3 20255d after period end

Aug 5, 2025

10-QQ2 20254d after period end

May 6, 2025

10-QQ1 20254d after period end

Mar 11, 2025

10-KQ4 20244d after period end

Mar 11, 2025

10-KFY 202570d after period end

Nov 7, 2024

10-QQ3 20243d after period end

Loading company sections...

Corbus Pharmaceuticals Holdings, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness